siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications

July 26, 2026

Inside Therapeutics USA

Overview

Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation technologies. LNP-mediated delivery achieved clinical success with Alnylam Pharmaceuticals’ Patisiran, establishing safe and efficient RNA delivery to the liver. GalNAc-siRNA conjugates are also highlighted as a highly effective approach for targeting hepatocytes, with both technologies significantly expanding the clinical applicability of siRNA therapeutics.

In Depth

Key Findings

Small interfering RNA (siRNA) represents a groundbreaking therapeutic modality capable of sequence-specific gene silencing by targeting and degrading messenger RNA (mRNA). Inside Therapeutics elaborates on how the major challenges associated with siRNA—namely, in vivo instability and efficient delivery to target cells—have been effectively addressed through advancements in lipid nanoparticle (LNP) and N-acetylgalactosamine (GalNAc) conjugation technologies. These delivery platforms have been instrumental in enabling the clinical success of siRNA therapeutics and significantly broadening their therapeutic scope.

Technical and Clinical Details

siRNAs are 20-25 nucleotide long double-stranded RNA molecules that activate the RNA interference (RNAi) pathway to specifically suppress the expression of disease-causing genes. However, naked siRNA molecules are highly susceptible to nuclease degradation in biological fluids and face difficulties crossing cell membranes. To circumvent these limitations, two primary delivery strategies have been developed:

Lipid Nanoparticles (LNPs): LNPs encapsulate siRNA molecules, enhancing their stability in vivo and facilitating efficient cellular uptake. Alnylam Pharmaceuticals’ Patisiran (Onpattro), approved by the FDA in 2018 for the treatment of transthyretin-mediated amyloidosis, was the first LNP-mediated siRNA therapeutic, firmly establishing the clinical efficacy and safety of LNP technology. LNPs primarily excel in delivering RNA to the liver.
N-acetylgalactosamine (GalNAc) Conjugation: GalNAc is a sugar moiety that specifically binds to the asialoglycoprotein receptor (ASGPR) predominantly expressed on the surface of hepatocytes. Conjugating siRNAs with GalNAc enables highly efficient and specific delivery to liver cells. This approach has also seen success with multiple siRNA therapeutics, such as Givosiran and Lumasiran (targeting the same disease as Patisiran), proving particularly useful for treating liver-centric diseases.

These sophisticated delivery technologies have propelled siRNA into clinical development across a wide range of therapeutic areas, including genetic disorders, infectious diseases, and oncology. For instance, inclisiran, an siRNA therapeutic for hypercholesterolemia, utilizes GalNAc conjugation, allowing for convenient subcutaneous administration typically once every 3 to 6 months.

Background and Context

The discovery of RNAi, honored with a Nobel Prize in 2006, sparked immense excitement for siRNA as a revolutionary gene-targeting therapy. However, delivery challenges long remained a significant barrier to its clinical translation. The establishment of LNP and GalNAc conjugation technologies was a breakthrough, transforming siRNA from a powerful research tool into viable therapeutic agents. This pivotal advancement has accelerated pharmaceutical industry investment in RNA therapeutics, with numerous companies now building robust siRNA pipelines.

Strategic Significance and Outlook

LNP and GalNAc conjugation technologies will continue to evolve as foundational platforms for siRNA therapeutics. Optimizing LNP delivery to extrahepatic organs and developing novel targeting ligands will be key to further broadening siRNA’s therapeutic reach. For example, achieving effective siRNA delivery to previously challenging organs such as the lungs, central nervous system, and solid tumors could lead to new breakthroughs in the treatment of chronic diseases and cancer. These technological advancements are expected to contribute significantly to the progress of personalized medicine and address a greater number of unmet medical needs.

Source: https://insidetx.com/applications/payloads/sirna/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.